X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (27) 27
humans (25) 25
article (20) 20
human immunodeficiency virus--hiv (17) 17
immunology (16) 16
female (13) 13
male (13) 13
adult (12) 12
antibodies (11) 11
hiv infection (11) 11
hiv-1 - immunology (11) 11
middle aged (11) 11
animals (10) 10
hiv (10) 10
infectious diseases (10) 10
in-vivo (9) 9
multidisciplinary sciences (9) 9
therapy (9) 9
virology (9) 9
viruses (9) 9
antiretroviral drugs (8) 8
antiretroviral therapy (8) 8
broadly neutralizing antibodies (8) 8
health aspects (8) 8
young adult (8) 8
hiv infections - immunology (7) 7
hiv infections - virology (7) 7
immunotherapy (7) 7
infection (7) 7
medicine, research & experimental (7) 7
monoclonal antibodies (7) 7
research (7) 7
viremia (7) 7
adolescent (6) 6
antiviral agents (6) 6
care and treatment (6) 6
clinical trials (6) 6
hiv infections - drug therapy (6) 6
hiv-1 - genetics (6) 6
immune response (6) 6
immunoglobulins (6) 6
mice (6) 6
t cells (6) 6
analysis (5) 5
antibodies, neutralizing - administration & dosage (5) 5
antibodies, neutralizing - immunology (5) 5
antibodies, neutralizing - therapeutic use (5) 5
binding sites (5) 5
biochemistry & molecular biology (5) 5
cell biology (5) 5
dendritic cells (5) 5
dendritic cells - immunology (5) 5
deoxyribonucleic acid--dna (5) 5
drug therapy (5) 5
hiv antibodies - administration & dosage (5) 5
monoclonal-antibodies (5) 5
t-cells (5) 5
virus diseases (5) 5
aged (4) 4
aids (4) 4
antigens (4) 4
antiretroviral agents (4) 4
cd4-positive t-lymphocytes - immunology (4) 4
hiv antibodies (4) 4
hiv antibodies - immunology (4) 4
hiv antibodies - therapeutic use (4) 4
hiv infections - therapy (4) 4
human immunodeficiency virus (4) 4
humanized mice (4) 4
immunity (4) 4
infections (4) 4
methods (4) 4
passive transfer (4) 4
potent (4) 4
prevention (4) 4
proliferation (4) 4
proteins (4) 4
reservoir (4) 4
t cell receptors (4) 4
usage (4) 4
vaccines (4) 4
viral antibodies (4) 4
viral load (4) 4
acquired immune deficiency syndrome (3) 3
acquired immune deficiency syndrome--aids (3) 3
aids vaccines - administration & dosage (3) 3
antibodies, monoclonal - administration & dosage (3) 3
antibodies, monoclonal - therapeutic use (3) 3
antibodies, neutralizing - pharmacology (3) 3
b cells (3) 3
biological sciences (3) 3
biology (3) 3
brazil (3) 3
carboxymethylcellulose sodium - analogs & derivatives (3) 3
carboxymethylcellulose sodium - pharmacology (3) 3
cd4 antigen (3) 3
cd4 t-cells (3) 3
cross-sectional studies (3) 3
cytokines (3) 3
cytokines - secretion (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2019 - 2021
Journal Article
The Lancet HIV, ISSN 2352-3018, 04/2019, Volume 6, Issue 4, pp. e207 - e208
Journal Article
Nature, ISSN 0028-0836, 06/2015, Volume 522, Issue 7557, pp. 487 - 491
HIV-1 immunotherapy with a combination of first generation monoclonal antibodies was largely ineffective in pre-clinical and clinical settings and was... 
THERAPY | VIRUS | HIV-1 NEUTRALIZATION | GENETIC-DETERMINANTS | IMMUNOTHERAPY | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | IN-VIVO | VACCINE | MICE | MONOCLONAL-ANTIBODIES | Antibodies, Neutralizing - administration & dosage | Humans | Middle Aged | Viremia - therapy | Molecular Sequence Data | Antibodies, Monoclonal - therapeutic use | Male | Case-Control Studies | HIV Envelope Protein gp120 - immunology | Young Adult | HIV Infections - immunology | Antibodies, Neutralizing - immunology | HIV Antibodies - adverse effects | HIV Antibodies - immunology | Time Factors | HIV-1 - chemistry | Antibodies, Neutralizing - therapeutic use | Adult | Antibodies, Neutralizing - adverse effects | Female | HIV Antibodies - therapeutic use | HIV Envelope Protein gp120 - chemistry | HIV Antibodies - pharmacology | Binding Sites | Antibodies, Monoclonal - immunology | Amino Acid Sequence | Immunization, Passive - methods | HIV-1 - drug effects | HIV Infections - virology | Antibodies, Monoclonal - pharmacokinetics | Antibodies, Neutralizing - pharmacology | HIV Antibodies - administration & dosage | Viral Load - immunology | HIV-1 - immunology | Viremia - virology | Antibodies, Monoclonal - administration & dosage | HIV Infections - therapy | Viremia - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Evolution, Molecular | Viral antibodies | Virus diseases | Physiological aspects | Antibodies | HIV infection | Antigens | Immunoglobulins | Human immunodeficiency virus--HIV | Immunotherapy | Infections | Drug dosages | Binding sites | Immune system
Journal Article
Nature, ISSN 0028-0836, 07/2016, Volume 535, Issue 7613, pp. 556 - 560
Interruption of combination antiretroviral therapy in HIV-1-infected individuals leads to rapid viral rebound. Here we report the results of a phase IIa open... 
POTENT | REPLICATION | GENETIC-DETERMINANTS | BROADLY NEUTRALIZING ANTIBODIES | MULTIDISCIPLINARY SCIENCES | PASSIVE TRANSFER | SEQUENCE | CD4 BINDING | ANTIRETROVIRAL THERAPY | INFECTION | MONOCLONAL-ANTIBODIES | Anti-HIV Agents - pharmacology | Antibodies, Neutralizing - administration & dosage | Disease Reservoirs - virology | Humans | Middle Aged | Male | Proviruses - immunology | Anti-HIV Agents - administration & dosage | Tissue Distribution | Young Adult | HIV Infections - immunology | Proviruses - drug effects | Antibodies, Neutralizing - immunology | HIV-1 - growth & development | HIV Antibodies - immunology | HIV Envelope Protein gp160 - chemistry | Time Factors | Antibodies, Neutralizing - therapeutic use | Binding Sites - immunology | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Antibodies - therapeutic use | Historically Controlled Study | Binding Sites - drug effects | HIV Envelope Protein gp160 - metabolism | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | HIV Antibodies - administration & dosage | Viral Load - immunology | Proviruses - growth & development | HIV-1 - immunology | HIV Envelope Protein gp160 - antagonists & inhibitors | Adolescent | HIV Infections - drug therapy | Aged | HIV Envelope Protein gp160 - immunology | Viral Load - drug effects | CD4 Antigens - metabolism | Prevention | Antiviral agents | HIV antibodies | Dosage and administration | Host-virus relationships | Drug therapy, Combination | Drug therapy | Health aspects | HIV infection | Methods | Clinical trials | Antiretroviral drugs | Immunoglobulins | Human immunodeficiency virus--HIV | Binding sites
Journal Article
Science, ISSN 0036-8075, 05/2016, Volume 352, Issue 6288, pp. 997 - 1001
Journal Article
Nature Medicine, ISSN 1078-8956, 02/2017, Volume 23, Issue 2, pp. 185 - 191
Journal Article
AIDS Research and Human Retroviruses, ISSN 0889-2229, 10/2018, Volume 34, Issue S1, pp. 1 - 407
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 12/2016, Volume 113, Issue 49, pp. E7908 - E7916
HIV-1–infected individuals harbor a latent reservoir of infected CD4⁺ T cells that is not eradicated by antiretroviral therapy (ART). This reservoir presents... 
Replication-competent | Reservoir | Method | HIV | Culture | method | PERSISTENCE | MULTIDISCIPLINARY SCIENCES | CD4(+) T-CELLS | PROLIFERATION | HIV-1-INFECTED CELLS | culture | BROADLY NEUTRALIZING ANTIBODIES | replication-competent | ACTIVE ANTIRETROVIRAL THERAPY | IN-VIVO | IMMUNODEFICIENCY-VIRUS TYPE-1 | INFECTED-CELLS | reservoir | LATENT RESERVOIR | Biological Sciences | PNAS Plus
Journal Article
Nature, ISSN 0028-0836, 09/2018, Volume 561, Issue 7724, pp. 479 - 484
Journal Article
Journal Article